Frank Lichtenberg
Names
| first: |
Frank |
| last: |
Lichtenberg |
Identifer
Contact
Affiliations
-
National Bureau of Economic Research (NBER) (weight: 30%)
-
CESifo (weight: 10%)
-
Columbia University
/ Graduate School of Business
/ Finance and Economics Department (weight: 60%)
Research profile
author of:
- The Impact and Organization of Publicly-Funded Research and development in the European Community (RePEc:adr:anecst:y:1998:i:49-50:p:199-222)
by Maryann P. Feldman & Frank R. Lichtenberg - Are the More Educated More Likely to Use New Drugs? (RePEc:adr:anecst:y:2005:i:79-80:p:671-696)
by Adriana Lleras-Muney & Frank R. Lichtenberg - The Relationship between Federal Contract R&D and Company R&D (RePEc:aea:aecrev:v:74:y:1984:i:2:p:73-78)
by Lichtenberg, Frank R - The Private R&D Investment Response to Federal Design and Technical Competitions (RePEc:aea:aecrev:v:78:y:1988:i:3:p:550-59)
by Lichtenberg, Frank R - Do (More and Better) Drugs Keep People Out of Hospitals? (RePEc:aea:aecrev:v:86:y:1996:i:2:p:384-88)
by Lichtenberg, Frank R - The Impact of New Drugs on US Longevity and Medical Expenditure, 1990–2003: Evidence from Longitudinal, Disease-Level Data (RePEc:aea:aecrev:v:97:y:2007:i:2:p:438-443)
by Frank R. Lichtenberg - Errors of Measurement in Output Deflators (RePEc:bes:jnlbes:v:7:y:1989:i:1:p:1-9)
by Lichtenberg, Frank R & Griliches, Zvi - Productivity and Changes in Ownership of Manufactoring Plants (RePEc:bin:bpeajo:v:18:y:1987:i:1987-3:p:643-684)
by Frank R. Lichtenberg & Donald Siegel - The Impact of Pharmaceutical Innovation on Premature Mortality, Hospital Separations, and Cancer Survival in Australia (RePEc:bla:ecorec:v:93:y:2017:i:302:p:353-378)
by Frank R. Lichtenberg - The Effect Of Control Changes On The Productivity Of U.S. Manufacturing Plants (RePEc:bla:jacrfn:v:2:y:1989:i:2:p:60-67)
by Frank R. Lichtenberg & Donald Siegel - The Effect of Government Funding on Private Industrial Research and Development: A Re-assessment (RePEc:bla:jindec:v:36:y:1987:i:1:p:97-104)
by Lichtenberg, Frank R - Contributions to Federal Election Campaigns by Government Contractors (RePEc:bla:jindec:v:38:y:1989:i:1:p:31-48)
by Lichtenberg, Frank R - Computer Use and Productivity Growth in US Federal Government Agencies, 1987–92 (RePEc:bla:jindec:v:46:y:1998:i:2:p:257-279)
by William Lehr & Frank R. Lichtenberg - Pharmaceutical Price Discrimination and Social Welfare (RePEc:bpj:capsoc:v:5:y:2010:i:1:n:2)
by Lichtenberg Frank R. - Pharmaceutical Innovation and U.S. Cancer Survival, 1992-2003: Evidence from Linked SEER-MEDSTAT Data (RePEc:bpj:fhecpo:v:10:y:2008:i:1:n:1)
by Lichtenberg Frank R. - Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A Reexamination Using Data from the U.S. and Australia (RePEc:bpj:fhecpo:v:13:y:2010:i:2:n:11)
by Lichtenberg Frank R. - The Effect of Pharmaceutical Innovation on Longevity: Patient Level Evidence from the 1996–2002 Medical Expenditure Panel Survey and Linked Mortality Public-use Files (RePEc:bpj:fhecpo:v:16:y:2013:i:1:p:1-33:n:1)
by Lichtenberg Frank R. - The Impact of Pharmaceutical Innovation on Cancer Mortality in Belgium, 2004–2012 (RePEc:bpj:fhecpo:v:20:y:2017:i:1:p:28:n:1)
by Lichtenberg Frank R. - The Impact of New Drug Launches on Hospitalization in 2015 for 67 Medical Conditions in 15 OECD Countries: A Two-Way Fixed-Effects Analysis (RePEc:bpj:fhecpo:v:21:y:2018:i:2:p:20:n:4)
by Lichtenberg Frank R. - The Impact of Biopharmaceutical Innovation on Disability, Social Security Recipiency, and Use of Medical Care of U.S. Community Residents, 1998–2015 (RePEc:bpj:fhecpo:v:24:y:2021:i:1:p:35-74:n:1)
by Lichtenberg Frank R. - The Effects of Medicare on Health Care Utilization and Outcomes (RePEc:bpj:fhecpo:v:5:y:2002:n:3)
by Lichtenberg Frank R. - The Impact of New Drug Launches on Longevity Growth in Nine Middle Eastern and African Countries, 2007–2015 (RePEc:bpj:rmeecf:v:14:y:2018:i:3:p:15:n:3)
by Lichtenberg Frank R - Using Linked Census R&D-Lrd Data To Analyze The Effect Of R&D Investment On Total Factor Productivity Growth (RePEc:cen:wpaper:89-2)
by Donald Siegel & Frank R Lichtenberg - The Effect Of Takeovers On The Employment And Wages Of Central-Office And Other Personnel (RePEc:cen:wpaper:89-3)
by Frank R Lichtenberg & Donald Siegel - The Effects Of Leveraged Buyouts On Productivity And Related Aspects Of Firm Behavior (RePEc:cen:wpaper:89-5)
by Frank R Lichtenberg & Donald Siegel - The Allocation of Publicly-Funded Biomedical Research (RePEc:ces:ceswps:_140)
by Frank Lichtenberg - Response to Baker and Fugh-Berman's Critique of my Paper, "Why has Longevity Increased more in some States than in others?" (RePEc:ces:ceswps:_2712)
by Frank Lichtenberg - The Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France (RePEc:ces:ceswps:_3095)
by Frank Lichtenberg - The Impact of Pharmaceutical Innovation on Longevity and Medical Expenditure in Sweden, 1997-2010: Evidence from Longitudinal, Disease-Level Data (RePEc:ces:ceswps:_3894)
by Frank Lichtenberg & Billie Pettersson - The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey (RePEc:ces:ceswps:_404)
by Frank Lichtenberg - Sources of U.S. Longevity Increase, 1960 -1997 (RePEc:ces:ceswps:_405)
by Frank Lichtenberg - The Impact of Recent Chemotherapy Innovation on the Longevity of Myeloma Patients: U.S. and International Evidence (RePEc:ces:ceswps:_4516)
by Frank Lichtenberg & Gisela Hostenkamp - Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010 (RePEc:ces:ceswps:_5166)
by Frank Lichtenberg - The impact of new drug launches on hospitalization in 2015 for 67 medical conditions in 15 OECD countries: a two-way fixed-effects analysis (RePEc:ces:ceswps:_7559)
by Frank R. Lichtenberg - Information technology and its impact on firm-level productivity: evidence from government and private data sources, 1977-1993 (RePEc:cje:issued:v:32:y:1999:i:2:p:335-362)
by Bill Lehr & Frank Lichtenberg - The Impact of New Drug Launch on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries (RePEc:ctl:louvde:v:84:y:2018:i:3:p:309-354)
by Frank R. LICHTENBERG - The Impact Of New Drug Launches On Life-Years Lost In 2015 From 19 Types Of Cancer In 36 Countries (RePEc:cup:demeco:v:84:y:2018:i:3:p:309-354_3)
by Lichtenberg, Frank R. - Spurious correlation in estimation of the health production function: A note (RePEc:ebl:ecbull:eb-10-00138)
by Sule Akkoyunlu & Frank R. Lichtenberg & Boriss Siliverstovs & Peter Zweifel - Managerial ownership and firm performance: A re-examination using productivity measurement (RePEc:eee:corfin:v:5:y:1999:i:4:p:323-339)
by Palia, Darius & Lichtenberg, Frank - IR & D project data and theories of R & D investment (RePEc:eee:dyncon:v:13:y:1989:i:2:p:271-282)
by Lichtenberg, Frank R. - International R&D spillovers: A comment (RePEc:eee:eecrev:v:42:y:1998:i:8:p:1483-1491)
by Lichtenberg, Frank R. & Pottelsberghe de la Potterie, Bruno v. - The effect of new drug approvals on HIV mortality in the US, 1987-1998 (RePEc:eee:ehbiol:v:1:y:2003:i:2:p:259-266)
by Lichtenberg, Frank R. - The impact of pharmaceutical innovation on longevity and medical expenditure in France, 2000–2009 (RePEc:eee:ehbiol:v:13:y:2014:i:c:p:107-127)
by Lichtenberg, Frank R. - The effect of pharmaceutical innovation on longevity: Evidence from the U.S. and 26 high-income countries (RePEc:eee:ehbiol:v:46:y:2022:i:c:s1570677x2200020x)
by Lichtenberg, Frank R. - Changing market opportunities and the structure of R & D investment : The case of energy (RePEc:eee:eneeco:v:9:y:1987:i:3:p:154-158)
by Lichtenberg, Frank R. - Economics of defense R&D (RePEc:eee:hdechp:1-15)
by Lichtenberg, Frank R. - The effect of pharmaceutical innovation on longevity, hospitalization and medical expenditure in Turkey, 1999–2010 (RePEc:eee:hepoli:v:117:y:2014:i:3:p:361-373)
by Lichtenberg, Frank R. & Tatar, Mehtap & Çalışkan, Zafer - Does competition stimulate drug utilization? The impact of changes in market structure on US drug prices, marketing and utilization (RePEc:eee:irlaec:v:32:y:2012:i:1:p:95-109)
by Duflos, Gautier & Lichtenberg, Frank R. - Ownership structure and corporate performance in Japan (RePEc:eee:japwor:v:6:y:1994:i:3:p:239-261)
by Lichtenberg, Frank R. & Pushner, George M. - The burden of government : , Stanford: Hoover Institution Press, 1986. x + 188 pp., $23.95 (RePEc:eee:jcecon:v:12:y:1988:i:2:p:304-305)
by Lichtenberg, Frank R. - Industrial de-diversification and its consequences for productivity (RePEc:eee:jeborg:v:18:y:1992:i:3:p:427-438)
by Lichtenberg, Frank R. - Labour market institutions, liquidity constraints, and macroeconomic stability (RePEc:eee:jeborg:v:28:y:1995:i:1:p:145-154)
by Lichtenberg, Frank R. - Rejoinder to comment by Maarten Vendrik (RePEc:eee:jeborg:v:28:y:1995:i:3:p:455-456)
by Lichtenberg, Frank R. - The effects of leveraged buyouts on productivity and related aspects of firm behavior (RePEc:eee:jfinec:v:27:y:1990:i:1:p:165-194)
by Lichtenberg, Frank R. & Siegel, Donald - How elastic is the government's demand for weapons? (RePEc:eee:pubeco:v:40:y:1989:i:1:p:57-78)
by Lichtenberg, Frank R. - Sources of U.S. longevity increase, 1960-2001 (RePEc:eee:quaeco:v:44:y:2004:i:3:p:369-389)
by Lichtenberg, Frank R. - Energy prices and induced innovation (RePEc:eee:respol:v:15:y:1986:i:2:p:67-75)
by Lichtenberg, Frank R. - Issues in measuring industrial R&D (RePEc:eee:respol:v:19:y:1990:i:2:p:157-163)
by Lichtenberg, Frank R. - The impact of recent chemotherapy innovation on the longevity of myeloma patients: US and international evidence (RePEc:eee:socmed:v:130:y:2015:i:c:p:162-171)
by Hostenkamp, Gisela & Lichtenberg, Frank R. - Pharmaceutical innovation and mortality in the United States, 1960-2000. A commentary on Schnittker and Karandinos (RePEc:eee:socmed:v:70:y:2010:i:7:p:969-971)
by Lichtenberg, Frank - The impact of therapeutic procedure innovation on hospital patient longevity: Evidence from Western Australia, 2000–2007 (RePEc:eee:socmed:v:77:y:2013:i:c:p:50-59)
by Lichtenberg, Frank R. - The impact of biomedical innovation on longevity and health (RePEc:elg:eechap:19760_23)
by Frank R. Lichtenberg - Unknown item RePEc:eme:ahes11:s0731-2199(08)19005-7 (chapter)
- Unknown item RePEc:eme:ahes11:s0731-2199(2010)0000022015 (chapter)
- Unknown item RePEc:eme:ahes11:s0731-2199(2012)0000023006 (chapter)
- Pharmaceutical innovation and the longevity of Australians: A first look (RePEc:eme:aheszz:s0731-2199(08)19005-7)
by Frank R. Lichtenberg & Gautier Duflos - The effect of drug vintage on survival: Micro evidence from Puerto Rico's Medicaid program (RePEc:eme:aheszz:s0731-2199(2010)0000022015)
by Frank R. Lichtenberg - The Effect of Pharmaceutical Innovation on the Functional Limitations of Elderly Americans: Evidence from the 2004 National Nursing Home Survey (RePEc:eme:aheszz:s0731-2199(2012)0000023006)
by Frank R. Lichtenberg - The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries (RePEc:ess:wpaper:id:12757)
by Frank R. Lichtenberg - The benefits to society of new drugs: a survey of the econometric evidence (RePEc:fip:feddpr:y:2003:i:sep:p:43-59)
by Frank R. Lichtenberg - The European Strategic Program for Research in Information Technologie (ESPRIT): An Ex-Post Analysis (RePEc:fth:colubu:96-09)
by Lichtenberg, F.R. - Computer Use and Productivity Growth in federal Government Agencies (RePEc:fth:colubu:96-10)
by Lichtenberg, F.R. & Lehr, B. - The Effect of New Political Administration on Federal Government Productivity and Employment (RePEc:fth:colubu:96-11)
by Lichtenberg, F.R. - Government Subsidies To Private Military R&D Investmen: Dod'S Ir&D Policy (RePEc:fth:colubu:fb-_88-01)
by Lichtenberg, F.R. - Crowding Out: The Impact Of The Strategic Defense Initiative On U.S. Civilian R&D Investment And Industrial Competitiveness (RePEc:fth:colubu:fb-_88-19)
by Lichtenberg, F.R. - How Elastic Is The Government'S Demand For Weapons? (RePEc:fth:colubu:fb-_88-39)
by Lichtenberg, F.R. - The Effect Of Takeovers On The Employment And Wages Of Central-Office And Other Personnel (RePEc:fth:colubu:fb-_89-05)
by Lichtenberg, F.R. & Siegel, D. - Contributions To Federal Election Campaigns By Government Contractors (RePEc:fth:colubu:fb-_89-06)
by Lichtenberg, F.R. - The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the US (RePEc:har:wpaper:0209)
by Frank R. Lichtenberg & Tomas J. Philipson - Are patients more adherent to newer drugs? (RePEc:kap:hcarem:v:23:y:2020:i:4:d:10.1007_s10729-020-09513-5)
by Katharina E. Blankart & Frank R. Lichtenberg - The quality of medical care, behavioral risk factors, and longevity growth (RePEc:kap:ijhcfe:v:11:y:2011:i:1:p:1-34)
by Frank Lichtenberg - The impact of pharmaceutical innovation on premature cancer mortality in Canada, 2000–2011 (RePEc:kap:ijhcfe:v:15:y:2015:i:3:p:339-359)
by Frank Lichtenberg - Has pharmaceutical innovation reduced the average cost of U.S. health care episodes? (RePEc:kap:ijhcfe:v:24:y:2024:i:1:d:10.1007_s10754-023-09363-y)
by Frank R. Lichtenberg - The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982–2001 (RePEc:kap:ijhcfe:v:5:y:2005:i:1:p:47-73)
by Frank Lichtenberg - Book Reviews (RePEc:kap:jeczfn:v:63:y:1996:i:3:p:325-345)
by J. Strand & M. Marchand & Y. Chung & R. Färe & F. Lichtenberg & W. Rogerson & J. Weidmann & P. Kort & P. Schönfeld - The Managerial Response to Regulation of Financial Reporting for Segments of a Business Enterprise (RePEc:kap:regeco:v:3:y:1991:i:3:p:241-49)
by Lichtenberg, Frank R - The Effects of Mergers on Prices, Costs, And Capacity Utilization in the U.S. Air Transportation Industry, 1970-84 (RePEc:lev:wrkpap:wp_32)
by Frank R. Lichtenberg & Moshe Kim - Industrial De-Diversification and Its Consequences for Productivity (RePEc:lev:wrkpap:wp_35)
by Frank R. Lichtenberg - The Impact of Hospital Quality-Related Practices on Health Outcomes (RePEc:max:cprwps:18)
by Deborah A. Freund & Frank R. Lichtenberg - R&D and Productivity Growth at the Industry Level: Is There Still a Relationship? (RePEc:nbr:nberch:10062)
by Zvi Griliches & Frank R. Lichtenberg - Pharmaceutical Knowledge-Capital Accumulation and Longevity (RePEc:nbr:nberch:10623)
by Frank R. Lichtenberg - Are the More Educated More Likely to Use New Drugs? (RePEc:nbr:nberch:12250)
by Adriana Lleras-Muney & Frank R. Lichtenberg - The Impact of Biomedical Research on U.S. Cancer Mortality: A Bibliometric Analysis (RePEc:nbr:nberch:13114)
by Frank R. Lichtenberg - The Value of Cytochrome P450 2C19 Pharmacogenomic Information for Patients Receiving Clopidogrel Therapy Following a Major Cardiovascular Event: Evidence from Geisinger (RePEc:nbr:nberch:13993)
by Rebecca A. Pulk & Jove Graham & Frank R. Lichtenberg & Daniel Maeng & Marc S. Williams & Eric Wright - The Allocation of Publicly Funded Biomedical Research (RePEc:nbr:nberch:7642)
by Frank R. Lichtenberg - The Effects of Medicare on Health Care Utilization and Outcomes (RePEc:nbr:nberch:9857)
by Frank R. Lichtenberg - Pharmaceutical Innovation and US Cancer Survival, 1992-2003: Evidence from Linked SEER-MEDSTAT Data (RePEc:nbr:nberch:9894)
by Frank R. Lichtenberg - Training, Tenure, and Productivity (RePEc:nbr:nberwo:0671)
by Frank R. Lichtenberg - R and D and Productivity at the Industry Level: Is There Still a Relationship? (RePEc:nbr:nberwo:0850)
by Zvi Griliches & Frank R. Lichtenberg - The Expanding Pharmaceutical Arsenal in the War on Cancer (RePEc:nbr:nberwo:10328)
by Frank R. Lichtenberg - The Effect of Drug Vintage on Survival: Micro Evidence from Puerto Rico's Medicaid Program (RePEc:nbr:nberwo:10884)
by Frank R. Lichtenberg - The Impact of New Laboratory Procedures and Other Medical Innovations on the Health of Americans, 1990-2003: Evidence from Longitudinal, Disease-Level Data (RePEc:nbr:nberwo:12120)
by Frank R. Lichtenberg - The Impact of Increased Utilization of HIV Drugs on Longevity and Medical Expenditures: An Assessment Based on Aggregate U.S. Time-Series Data (RePEc:nbr:nberwo:12406)
by Frank R. Lichtenberg - Importation and Innovation (RePEc:nbr:nberwo:12539)
by Frank R. Lichtenberg - Have Newer Cardiovascular Drugs Reduced Hospitalization? Evidence From Longitudinal Country-Level Data on 20 OECD Countries, 1995-2003 (RePEc:nbr:nberwo:14008)
by Frank R. Lichtenberg - Pharmaceutical innovation and the longevity of Australians: a first look (RePEc:nbr:nberwo:14009)
by Frank R. Lichtenberg & Gautier Duflos - The Quality of Medical Care, Behavioral Risk Factors, and Longevity Growth (RePEc:nbr:nberwo:15068)
by Frank R. Lichtenberg - Has medical innovation reduced cancer mortality? (RePEc:nbr:nberwo:15880)
by Frank R. Lichtenberg - Are Increasing 5-Year Survival Rates Evidence of Success Against Cancer? A reexamination using data from the U.S. and Australia (RePEc:nbr:nberwo:16051)
by Frank R. Lichtenberg - The Comparative Advantage of Educated Workers in Implementing New Technology: Some Empirical Evidence (RePEc:nbr:nberwo:1718)
by Ann P. Bartel & Frank R. Lichtenberg - The Impact of Therapeutic Procedure Innovation on Hospital Patient Longevity: Evidence from Western Australia, 2000-2007 (RePEc:nbr:nberwo:17414)
by Frank R. Lichtenberg - The Effect of Pharmaceutical Innovation on the Functional Limitations of Elderly Americans Evidence from the 2004 National Nursing Home Survey (RePEc:nbr:nberwo:17750)
by Frank R. Lichtenberg - Pharmaceutical Innovation and Longevity Growth in 30 Developing and High-income Countries, 2000-2009 (RePEc:nbr:nberwo:18235)
by Frank R. Lichtenberg - The Effect of Pharmaceutical Innovation on Longevity: Patient-Level Evidence from the 1996-2002 Medical Expenditure Panel Survey and Linked Mortality Public-Use Files (RePEc:nbr:nberwo:18552)
by Frank R. Lichtenberg - The Impact of Biomedical Knowledge Accumulation on Mortality: A Bibliometric Analysis of Cancer Data (RePEc:nbr:nberwo:19593)
by Frank R. Lichtenberg - Private Investment in R&D to Signal Ability to Perform Government Contracts (RePEc:nbr:nberwo:1974)
by Frank R. Lichtenberg - Errors of Measurement in Output Deflators (RePEc:nbr:nberwo:2000)
by Frank R. Lichtenberg & Zvi Griliches - The Impact of Pharmaceutical Innovation on Premature Cancer Mortality in Canada, 2000-2011 (RePEc:nbr:nberwo:21239)
by Frank R. Lichtenberg - Listen to your Doctor, or else!: Medication Under-use and Overuse and Long-term Health Outcomes of Danish Diabetes Patients (RePEc:nbr:nberwo:21780)
by Gisela Hostenkamp & Frank R. Lichtenberg - The Impact of Public and Private Research Support on Premature Cancer Mortality and Hospitalization in the U.S., 1999-2013 (RePEc:nbr:nberwo:23241)
by Frank R. Lichtenberg - The Impact of New Drug Launches on Life-Years Lost in 2015 from 19 Types of Cancer in 36 Countries (RePEc:nbr:nberwo:24536)
by Frank R. Lichtenberg - The Long-run Impact of New Medical Ideas on Cancer Survival and Mortality (RePEc:nbr:nberwo:25328)
by Frank R. Lichtenberg - How Many Life-Years Have New Drugs Saved? A 3-Way Fixed-Effects Analysis of 66 Diseases in 27 Countries, 2000-2013 (RePEc:nbr:nberwo:25483)
by Frank R. Lichtenberg - IR&D Project Data and Theories of R&D Investment (RePEc:nbr:nberwo:2720)
by Frank R. Lichtenberg - Technical Change, Learning, and Wages (RePEc:nbr:nberwo:2732)
by Ann P. Bartel & Frank R. Lichtenberg - Government Subsidies to Private Military R&D Investment: DOD's IR&D Policy (RePEc:nbr:nberwo:2745)
by Frank R. Lichtenberg - The Effect of Takeovers on the Employment and Wages of Central-Office and Other Personnel (RePEc:nbr:nberwo:2895)
by Frank Lichtenberg & Donald Siegel - The Impact of R&D Investment On Productivity - New Evidence Using Linked R&D-LRD Data (RePEc:nbr:nberwo:2901)
by Frank R. Lichtenberg & Donald Siegel - The Effects of Leveraged Buyouts on Productivity and Related Aspects of Firm Behavior (RePEc:nbr:nberwo:3022)
by Frank R. Lichtenberg & Donald Siegel - How Elastic is the Government's Demand for Weapons? (RePEc:nbr:nberwo:3025)
by Frank R. Lichtenberg - The Effects of Off-label Drug Use on Disability and Medical Expenditure (RePEc:nbr:nberwo:30440)
by Katharina E. Blankart & Frank R. Lichtenberg - The Effects of Mergers on Prices, Costs, and Capacity Utilization in the U.S. Air Transportation Industry, 1970-84 (RePEc:nbr:nberwo:3197)
by Frank R. Lichtenberg & Moshe Kim - Industrial De-Diversification and its Consequences for Productivity (RePEc:nbr:nberwo:3231)
by Frank R. Lichtenberg - Labor Market Institutions, Liquidity Constraints, and Macroeconomic Stability (RePEc:nbr:nberwo:3926)
by Frank R. Lichtenberg - Ownership Structure and Corporate Performance in Japan (RePEc:nbr:nberwo:4092)
by Frank R. Lichtenberg & George M. Pushner - R&D Investment and International Productivity Differences (RePEc:nbr:nberwo:4161)
by Frank R. Lichtenberg - The Output Contributions of Computer Equipment and Personnel: A Firm- Level Analysis (RePEc:nbr:nberwo:4540)
by Frank R. Lichtenberg - The Effect of Pharmaceutical Utilization and Innovation on Hospitalization and Mortality (RePEc:nbr:nberwo:5418)
by Frank R. Lichtenberg - The Effect of New Political Administration on Federal Government Productivity and Employment (RePEc:nbr:nberwo:5601)
by Frank R. Lichtenberg - Computer Use and Productivity Growth in Federal Government Agencies, 1987 to 1992 (RePEc:nbr:nberwo:5616)
by William Lehr & Frank R. Lichtenberg - International R&D Spillovers: A Re-Examination (RePEc:nbr:nberwo:5668)
by Frank Lichtenberg & Bruno van Pottelsberghe de la Potterie - The Impact and Organization of Publicly-Funded Research and Development in the European Community (RePEc:nbr:nberwo:6040)
by Maryann P. Feldman & Frank R. Lichtenberg - Pharmaceutical Innovation, Mortality Reduction, and Economic Growth (RePEc:nbr:nberwo:6569)
by Frank R. Lichtenberg - The Allocation of Publicly-Funded Biomedical Research (RePEc:nbr:nberwo:6601)
by Frank R. Lichtenberg - The Benefits and Costs of Newer Drugs: Evidence from the 1996 Medical Expenditure Panel Survey (RePEc:nbr:nberwo:8147)
by Frank R. Lichtenberg - The Effect of New Drugs on Mortality from Rare Diseases and HIV (RePEc:nbr:nberwo:8677)
by Frank R. Lichtenberg - Sources of U.S. Longevity Increase, 1960-1997 (RePEc:nbr:nberwo:8755)
by Frank R. Lichtenberg - Benefits and Costs of Newer Drugs: An Update (RePEc:nbr:nberwo:8996)
by Frank Lichtenberg - The Effect of Changes in Drug Utilization on Labor Supply and Per Capita Output (RePEc:nbr:nberwo:9139)
by Frank R. Lichtenberg - The Effect of Education on Medical Technology Adoption: Are the More Educated More Likely to Use New Drugs (RePEc:nbr:nberwo:9185)
by Adriana Lleras-Muney & Frank R. Lichtenberg - The Dual Effects of Intellectual Property Regulations: Within- and Between- Patent Competition in the US Pharmaceuticals Industry (RePEc:nbr:nberwo:9303)
by Frank R. Lichtenberg & Tomas J. Philipson - Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as "equipment for your health" (RePEc:nbr:nberwo:9351)
by Frank R. Lichtenberg & Suchin Virabhak - Does Misery Love Company? Evidence from pharmaceutical markets before and after the Orphan Drug Act (RePEc:nbr:nberwo:9750)
by Frank R. Lichtenberg & Joel Waldfogel - The impact of new drug launches on longevity: evidence from longitudinal disease-level data from 52 countries, 1982-2001 (RePEc:nbr:nberwo:9754)
by Frank R. Lichtenberg - Using Patents Data to Map Technical Change in Health-Related Areas (RePEc:oec:stiaaa:2002/16-en)
by Frank Lichtenberg & Suchin Virabhak - Has Medical Innovation Reduced Cancer Mortality? (RePEc:oup:cesifo:v:60:y:2014:i:1:p:135-177.)
by Frank R. Lichtenberg - The Impact of R&D Investment on Productivity--New Evidence Using Linked R&D-LRD Data (RePEc:oup:ecinqu:v:29:y:1991:i:2:p:203-29)
by Lichtenberg, Frank R & Siegel, Donald - The expanding pharmaceutical arsenal in the war on cancer (RePEc:red:sed004:204)
by Frank R. Lichtenberg - The Health Impact of, and access to, New Drugs in Korea (RePEc:ris:eaerev:0374)
by Lichtenberg, Frank - The Impact of Public and Private Research on Premature Cancer Mortality and Hospitalization in the United States, 1999-2013 (RePEc:sae:amerec:v:63:y:2018:i:2:p:147-165)
by Frank R. Lichtenberg - Has Using Newer Drugs Reduced Admissions to Hospitals and Nursing Homes? (RePEc:ses:arsjes:2006-v-11)
by Frank Lichtenberg - Spurious correlation in estimation of the health production function: A note (RePEc:soz:wpaper:0903)
by Sule Akkoyunlu & Frank R. Lichtenberg & Boriss Siliverstovs & Peter Zweifel - Impact of Specialization on Health Outcomes – Evidence from U.S. Cancer Data (RePEc:soz:wpaper:1011)
by Frank R. Lichtenberg & Johannes Schoder - The Impact of Pharmaceutical Innovation on Premature Mortality, Cancer Mortality, and Hospitalization in Slovenia, 1997–2010 (RePEc:spr:aphecp:v:13:y:2015:i:2:p:207-222)
by Frank Lichtenberg - The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999–2007 (RePEc:spr:eujhec:v:14:y:2013:i:1:p:41-56)
by Frank Lichtenberg - The effects of dynamic and static competition on prescription drug prices in Denmark, 1997–2017 (RePEc:spr:joevec:v:32:y:2022:i:4:d:10.1007_s00191-022-00777-4)
by Frank R. Lichtenberg - The impact of pharmaceutical innovation on cancer mortality in Mexico, 2003–2013 (RePEc:spr:laecrv:v:26:y:2017:i:1:d:10.1007_s40503-017-0045-6)
by Frank R. Lichtenberg - The Effect of Using Newer Drugs on Admissions of Elderly Americans to Hospitals and Nursing Homes: State-level Evidence from 1997 to 2003 (RePEc:spr:pharme:v:24:y:2006:i:3:p:5-25)
by Frank Lichtenberg - Contribution of Pharmaceutical Innovation to Longevity Growth in Germany and France, 2001–7 (RePEc:spr:pharme:v:30:y:2012:i:3:p:197-211)
by Frank Lichtenberg - The association between pharmaceutical innovation and both premature mortality and hospital utilization in Switzerland, 1996–2019 (RePEc:spr:sjecst:v:158:y:2022:i:1:d:10.1186_s41937-022-00086-4)
by Frank R. Lichtenberg - Importation And Innovation (RePEc:taf:ecinnt:v:16:y:2007:i:6:p:403-417)
by Frank R. Lichtenberg - The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978-2004 (RePEc:taf:ecinnt:v:18:y:2009:i:5:p:407-428)
by Frank Lichtenberg - The impact of pharmaceutical innovation on longevity and medical expenditure in Sweden, 1997-2010: evidence from longitudinal, disease-level data (RePEc:taf:ecinnt:v:23:y:2014:i:3:p:239-273)
by Frank R. Lichtenberg & Billie Pettersson - The long-run impact of new medical ideas on cancer survival and mortality (RePEc:taf:ecinnt:v:28:y:2019:i:7:p:722-740)
by Frank R. Lichtenberg - The impact of biomedical innovation on the disability of elderly Medicare recipients, 2013–2019 (RePEc:taf:ecinnt:v:33:y:2024:i:2:p:344-361)
by Frank R. Lichtenberg - Has Pharmaceutical Innovation Reduced Social Security Disability Growth? (RePEc:taf:ijecbs:v:18:y:2011:i:2:p:293-316)
by Frank Lichtenberg - Pharmaceutical Innovation, Longevity, and Medical Expenditure in Greece, 1995-2010 (RePEc:taf:ijecbs:v:22:y:2015:i:2:p:277-299)
by Frank R. Lichtenberg - Interindustry Technology Flows and Productivity Growth: A Re-examination (RePEc:tpr:restat:v:66:y:1984:i:2:p:324-29)
by Griliches, Zvi & Lichtenberg, Frank - The Comparative Advantage of Educated Workers in Implementing New Technology (RePEc:tpr:restat:v:69:y:1987:i:1:p:1-11)
by Bartel, Ann P & Lichtenberg, Frank R - Estimation of the Internal Adjustment Costs Model Using Longitudinal Establishment Data (RePEc:tpr:restat:v:70:y:1988:i:3:p:421-30)
by Lichtenberg, Frank R - Testing the Convergence Hypothesis (RePEc:tpr:restat:v:76:y:1994:i:3:p:576-79)
by Lichtenberg, Frank R - Does Foreign Direct Investment Transfer Technology Across Borders? (RePEc:tpr:restat:v:83:y:2001:i:3:p:490-497)
by Bruno Van Pottelsberghe De La Potterie & Frank Lichtenberg - The Impact of Pharmaceutical Innovation on Disability Days and the Use of Medical Services in the United States, 1997-2010 (RePEc:ucp:jhucap:doi:10.1086/679110)
by Frank R. Lichtenberg - The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the U.S. Pharmaceuticals Industry (RePEc:ucp:jlawec:doi:10.1086/374703)
by Frank R. Lichtenberg & Tomas J. Philipson - The Effect of Ownership Changes on the Employment and Wages of Central Office and Other Personnel (RePEc:ucp:jlawec:v:33:y:1990:i:2:p:383-408)
by Lichtenberg, Frank R & Siegel, Donald - Does foreign direct investment transfer technology across borders? (RePEc:ulb:ulbeco:2013/6221)
by Bruno Van Pottelsberghe & Frank Lichtenberg - International R&D spillovers comment (RePEc:ulb:ulbeco:2013/6233)
by Bruno Van Pottelsberghe & Frank Lichtenberg - Have newer cardiovascular drugs reduced hospitalization? Evidence from longitudinal country‐level data on 20 OECD countries, 1995–2003 (RePEc:wly:hlthec:v:18:y:2009:i:5:p:519-534)
by Frank R. Lichtenberg - Are drug prices subject to creative destruction? Evidence from the US, 1997–2017 (RePEc:wly:hlthec:v:30:y:2021:i:8:p:1910-1932)
by Frank R. Lichtenberg - Pharmaceutical-embodied technical progress, longevity, and quality of life: drugs as 'Equipment for Your Health' (RePEc:wly:mgtdec:v:28:y:2007:i:4-5:p:371-392)
by Frank R. Lichtenberg & Suchin Virabhak - Benefits and costs of newer drugs: an update (RePEc:wly:mgtdec:v:28:y:2007:i:4-5:p:485-490)
by Frank R. Lichtenberg - The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in The US Pharmaceuticals Industry (RePEc:zbw:cbscwp:178)
by Lichtenberg, Frank R. & Philipson, Tomas J. - The effects of off-label drug use on disability and medical expenditure (RePEc:zbw:rwirep:969)
by Blankart, Katharina & Lichtenberg, Frank R.